Nexien BioPharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2017 - 2019
Selling, General & Admin	0.12	0.16	0.28	0.56	1.84	2.64	Upgrade
Operating Expenses	0.12	0.16	0.28	0.56	1.84	2.64	Upgrade
Operating Income	-0.12	-0.16	-0.28	-0.56	-1.84	-2.64	Upgrade
Interest Expense	-0.07	-0.08	-0.08	-0.06	-0.02	-0	Upgrade
EBT Excluding Unusual Items	-0.19	-0.24	-0.36	-0.63	-1.86	-2.64	Upgrade
Asset Writedown	-	-	-	-	-	-0.04	Upgrade
Pretax Income	-0.19	-0.24	-0.36	-0.63	-1.86	-2.67	Upgrade
Net Income	-0.19	-0.24	-0.36	-0.63	-1.86	-2.67	Upgrade
Net Income to Common	-0.19	-0.24	-0.36	-0.63	-1.86	-2.67	Upgrade
Shares Outstanding (Basic)	70	66	62	58	55	54	Upgrade
Shares Outstanding (Diluted)	70	66	62	58	55	54	Upgrade
Shares Change (YoY)	8.06%	6.19%	7.73%	4.44%	2.76%	5.64%	Upgrade
EPS (Basic)	-0.00	-0.00	-0.01	-0.01	-0.03	-0.05	Upgrade
EPS (Diluted)	-0.00	-0.00	-0.01	-0.01	-0.03	-0.05	Upgrade
EBIT	-0.12	-0.16	-0.28	-0.56	-1.84	-2.64	Upgrade

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.